Rapid molecular tests for tuberculosis and tuberculosis drug resistance: provider and recipient views

Nora Engel; Eleanor A Ochodo; Perpetua Wanjiku Karanja; Bey-Marrié Schmidt; Ricky Janssen; Karen R Steingart; Sandy Oliver

doi:10.1002/14651858.CD014877

Rapid molecular tests for tuberculosis and tuberculosis drug resistance: provider and recipient views

Nora Engel, Eleanor A Ochodo, Perpetua Wanjiku Karanja, Bey-Marrié Schmidt, Ricky Janssen, Karen R Steingart, Sandy Oliver

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Objectives: This is a protocol for a Cochrane Review (qualitative). The objectives are as follows:. To synthesize end-user and professional user perspectives and experiences with low-complexity nucleic acid amplification tests (NAATs) for detection of tuberculosis and tuberculosis drug resistance. Review question What are the perspectives and experiences of people providing and receiving low-complexity NAATs to diagnose tuberculosis and tuberculosis drug resistance? Answering this question will allow us to identify the implications for effective implementation and health equity.

Original language	English
Article number	CD014877
Journal	Cochrane Database of Systematic Reviews
Volume	2021
Issue number	9
DOIs	https://doi.org/10.1002/14651858.CD014877
Publication status	Published - 3 Sept 2021
Externally published	Yes

Funding

The editorial base of the Cochrane Infectious Diseases Group (CIDG) is funded by UK aid from the UK government for the benefit of low-and middle-income countries (project number 300342-104). The views expressed do not necessarily reflect the UK government’s official policies. We are grateful to Vittoria Lutje, CIDG Information Specialist, for helping us with the search strategy. KRS: received funding from the World Health Organization (WHO) Global Tuberculosis Programme, Switzerland. Received additional financial support from Cochrane Infectious Diseases, UK; McGill University, Canada; Baylor College of Medicine, Houston; and the World Health Organization Global Tuberculosis Programme, Switzerland, for the preparation of related systematic reviews and educational materials; consultancy fees from Foundation for Innovative New Diagnostics (FIND), Switzerland (for the preparation of systematic reviews and GRADE tables); consultancy fees from Stellenbosch University, Stellenbosch (for guidance on evidence syntheses); and honoraria and travel support to attend WHO guideline meetings. This work was partly supported through a grant from the WHO Global Tuberculosis Programme, Agreement for Performance of Work (APW) (registration number 202582434). The views expressed in this review have not been influenced by, or necessarily reflect, WHO policy. We acknowledge the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Effective Practice and Organisation of Care (EPOC) Group. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health. SO: received funding from the READ-It programme, UK (project number 300342-104). The Academic Editor is Professor Paul Garner, and Sign-off Editor is Dr Hellen Gelband. The editorial base of the Cochrane Infectious Diseases Group (CIDG) is funded by UK aid from the UK government for the benefit of low- and middle-income countries (project number 300342-104). The views expressed do not necessarily reflect the UK government?s official policies. We are grateful to Vittoria Lutje, CIDG Information Specialist, for helping us with the search strategy. We acknowledge the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Effective Practice and Organisation of Care (EPOC) Group. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health. This work was partly supported through a grant from the WHO Global Tuberculosis Programme,?Agreement for Performance of Work (APW) (registration number 202582434). The views?expressed in this review have not been influenced by, or necessarily reflect, WHO policy.

Funders	Funder number
CIDG
EPOC
FIND
Foundation for Innovative New Diagnostics
National Health Service
Organisation of Care
Vittoria Lutje
World Health Organization	202582434
Baylor College of Medicine
McGill University
Government of the United Kingdom	300342-104
National Institute for Health Research
Universiteit Stellenbosch

Access to Document

10.1002/14651858.CD014877

Persistent URL (handle)

Copy link address

Cite this

@article{69dd8c6ff0eb421a868e098159bddcc7,

title = "Rapid molecular tests for tuberculosis and tuberculosis drug resistance: provider and recipient views",

abstract = "Objectives: This is a protocol for a Cochrane Review (qualitative). The objectives are as follows:. To synthesize end-user and professional user perspectives and experiences with low-complexity nucleic acid amplification tests (NAATs) for detection of tuberculosis and tuberculosis drug resistance. Review question What are the perspectives and experiences of people providing and receiving low-complexity NAATs to diagnose tuberculosis and tuberculosis drug resistance? Answering this question will allow us to identify the implications for effective implementation and health equity.",

author = "Nora Engel and Ochodo, {Eleanor A} and Karanja, {Perpetua Wanjiku} and Bey-Marri{\'e} Schmidt and Ricky Janssen and Steingart, {Karen R} and Sandy Oliver",

year = "2021",

month = sep,

day = "3",

doi = "10.1002/14651858.CD014877",

language = "English",

volume = "2021",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "Wiley",

number = "9",

}

TY - JOUR

T1 - Rapid molecular tests for tuberculosis and tuberculosis drug resistance

T2 - provider and recipient views

AU - Engel, Nora

AU - Ochodo, Eleanor A

AU - Karanja, Perpetua Wanjiku

AU - Schmidt, Bey-Marrié

AU - Janssen, Ricky

AU - Steingart, Karen R

AU - Oliver, Sandy

PY - 2021/9/3

Y1 - 2021/9/3

N2 - Objectives: This is a protocol for a Cochrane Review (qualitative). The objectives are as follows:. To synthesize end-user and professional user perspectives and experiences with low-complexity nucleic acid amplification tests (NAATs) for detection of tuberculosis and tuberculosis drug resistance. Review question What are the perspectives and experiences of people providing and receiving low-complexity NAATs to diagnose tuberculosis and tuberculosis drug resistance? Answering this question will allow us to identify the implications for effective implementation and health equity.

AB - Objectives: This is a protocol for a Cochrane Review (qualitative). The objectives are as follows:. To synthesize end-user and professional user perspectives and experiences with low-complexity nucleic acid amplification tests (NAATs) for detection of tuberculosis and tuberculosis drug resistance. Review question What are the perspectives and experiences of people providing and receiving low-complexity NAATs to diagnose tuberculosis and tuberculosis drug resistance? Answering this question will allow us to identify the implications for effective implementation and health equity.

UR - http://www.scopus.com/inward/record.url?scp=85118133578&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD014877

DO - 10.1002/14651858.CD014877

M3 - Article

SN - 1465-1858

VL - 2021

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 9

M1 - CD014877

ER -

Rapid molecular tests for tuberculosis and tuberculosis drug resistance: provider and recipient views

Abstract

Funding

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this